Skip to main
AGL
AGL logo

Agilon Health (AGL) Stock Forecast & Price Target

Agilon Health (AGL) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 18%
Buy 32%
Hold 41%
Sell 9%
Strong Sell 0%

Bulls say

Agilon Health Inc. demonstrated a robust financial performance in the fourth quarter, with total revenue increasing by 44.2% year-over-year, slightly exceeding projections. The company's Medicare Advantage (MA) membership grew by 36% to 527,000, supported by strong same geography growth, while improvements in medical cost data are anticipated to enhance future guidance and operational expectations. Additionally, operating expenses rose at a manageable rate, coming in below estimates, which reflects effective cost management despite the growth in membership and services.

Bears say

Agilon Health has demonstrated significant visibility issues, particularly in the second half of the year, with 2023 showcasing negative surprises in utilization forecasting that adversely impacted financial outcomes. The company reported an adjusted EBITDA of $(84.0) million for 4Q24, which was not only below expectations but also reflected a deteriorating medical margin driven by an unprofitable partnership slated for exit in 2025. Additionally, Agilon's projected decline in ACO REACH patients alongside elevated expenses related to Part D and supplemental benefits further accentuates the ongoing financial pressures facing the company, leading to a cautious outlook.

Agilon Health (AGL) has been analyzed by 22 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 32% recommend Buy, 41% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agilon Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agilon Health (AGL) Forecast

Analysts have given Agilon Health (AGL) a Buy based on their latest research and market trends.

According to 22 analysts, Agilon Health (AGL) has a Buy consensus rating as of Jul 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agilon Health (AGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.